<P>&nbsp;</P> <P align=justify><STRONG>Ohio-based clinical research organisation <A title="" href="http://www.medpace.com/" target=_blank>Medpace Inc </A>has announced the opening of a new fully-staffed, clinical operations office in <A title="" href="https://www.aderly.com/implantation-entreprise/lyon-european-city-france,p,5,EN.jsp" target=_blank>Lyon</A>, France</STRONG>. This addition brings the total number of Medpace offices across Europe to 11. The office will be led by Patrick Winkler, Medpace Country Manager, France. <STRONG>The Medpace France will provide service capabilities across Europe integrating international studies</STRONG>. The office will house regional project study managers, and clinical <A title="" href="https://www.aderly.com/pepiniere-entreprise/scientific-research-development-france,p,16,EN.jsp" target=_blank>research</A> associates who have the ability to monitor studies throughout Europe. <STRONG>The choice of Lyon seems obvious, considering its <A title="" href="https://www.aderly.com/reseau-de-transport/transport-network-lyon-france,p,13,EN.jsp" target=_blank>location in Europe </A>and the many skills of the region in the field of <A title="" href="https://www.aderly.com/biotechnologie-france-europe/life-science-biotechnology-cluster-france-europe,p,6,EN.jsp" target=_blank>biotechnologies</A>.</STRONG></P> <P align=justify><BR>The addition of these clinical experts and the new office will support an expansive Medpace European group delivering therapeutic study direction, full-service monitoring, and trial management services in tandem with existing European offices. <STRONG>The office in Lyon becomes part of an international network of clinical operations experts with the ability to conduct Phase I-IV studies</STRONG>, integrating early phase capabilities from Belgium, regulatory expertise from Germany, and safety expertise from the UK. A global leader in research-based drug and device development, Medpace builds strong strategic partnerships with select Sponsors to advance the most efficient and cost-effective path to drug and device approval.<BR></P>